Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry
Tóm tắt
Masitinib (MST) is an orally administered drug that targets mast cells and macrophages, important cells for immunity, by inhibiting a limited number of tyrosine kinases. It is currently registered in Europe and USA for the treatment of mast cell tumors in dogs. AB Science announced that the European Medicines Agency has accepted a conditional marketing authorization application for MST to treat amyotrophic lateral sclerosis. In our work, we focused on studying in vivo metabolism of MST in Sprague–Dawley rats. Single oral dose of MST (33 mg kg−1) was given to Sprague–Dawley rats (kept in metabolic cages) using oral gavage. Urine was collected and filtered at 0, 6, 12, 18, 24, 48, 72 and 96 h from MST dosing. An equal amount of ACN was added to urine samples. Both organic and aqueous layers were injected into liquid chromatography-tandem mass spectrometry (LC–MS/MS) to detect in vivo phase I and phase II MST metabolites. The current work reports the identification and characterization of twenty in vivo phase I and four in vivo phase II metabolites of MST by LC–MS/MS. Phase I metabolic pathways were reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation. Phase II metabolic pathways were the direct conjugation of MST, N-demethyl metabolites and oxidative metabolites with glucuronic acid. Part of MST dose was excreted unchanged in urine. The literature review showed no previous articles have been made on in vivo metabolism of MST or detailed structural identification of the formed in vivo phase I and phase II metabolites.
Tài liệu tham khảo
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96
Sinha R, El-Bayoumy K (2004) Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 4(1):13–28
Cozzi P, Mongelli N, Suarato A (2004) Recent anticancer cytotoxic agents. Curr Med Chem Anti Cancer Agents 4(2):93–121
Barinaga M (1997) From bench top to bedside. Science 278(5340):1036–1039
Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2):211–225
Özvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B (2005) Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updates 8(1):15–26
Steeghs N, Nortier JW, Gelderblom H (2007) Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14(2):942–953
Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S (2010) Tyrosine kinase inhibitors. Curr Cancer Drug Targets 10(5):462–483
Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O et al (2011) Safety of masitinib mesylate in healthy cats. J Vet Intern Med 25(2):297–302
Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF et al (2014) Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 91(1):98–111
Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N et al (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 4(9):e7258
Lortholary O, Chandesris MO, Livideanu CB, Paul C, Guillet G, Jassem E et al (2017) Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 389(10069):612–620
Kumar GN, Surapaneni S (2001) Role of drug metabolism in drug discovery and development. Med Res Rev 21(5):397–411
Kadi AA, Al-Shakliah NS, Yin W, Rahman AM (2017) In vitro investigation of metabolic profiling of newly developed topoisomerase inhibitors (ethyl fluorescein hydrazones, EtFLHs) in RLMs by LC–MS/MS. J Chromatogr B 1054:93–104
Rahman AM, Al-Shakliah NS, Yin W, Kadi AA (2017) In vitro Investigation of Metabolic Profiling of a Potent Topoisomerase Inhibitors Fluorescein Hydrazones (FLHs) in RLMs by LC-MS/MS. J Chromatogr B 1054:27–35
Attwa MW, Kadi AA, Darwish HW, Alrabiah H (2018) LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: phase I metabolic profiling. Clin Chim Acta 482:84–94
Attwa MW, Kadi AA, Darwish HW, Amer SM, Alrabiah H (2018) A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: application to metabolic stability investigation and excretion rate. Eur J Mass Spectrom 1469066718768327. https://doi.org/10.1177/1469066718768327
Masic LP (2011) Role of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship. Curr Drug Metab 12(1):35–50
Kadi AA, Attwa M, Darwish HW (2018) LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways. RSC Adv 8(3):1182–1190
Shin J-W, Seol I-C, Son C-G (2010) Interpretation of animal dose and human equivalent dose for drug development. J Korean Med 31(3):1–7
Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27–31
Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J Off Publ Fed Am Soc Exp Biol 22(3):659–661 (Epub 2007/10/19)
Varaprath S, Salyers KL, Plotzke KP, Nanavati S (1999) Identification of metabolites of octamethylcyclotetrasiloxane (D(4)) in rat urine. Drug Metab Dispos Biol Fate Chem 27(11):1267–1273
Bylda C, Thiele R, Kobold U, Volmer DA (2014) Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC–MS/MS. Analyst 139(10):2265–2276
Yoshida M, Akane A (1999) Subzero-temperature liquid − liquid extraction of benzodiazepines for high-performance liquid chromatography. Anal Chem 71(9):1918–1921
Valente IM, Gonçalves LM, Rodrigues JA (2013) Another glimpse over the salting-out assisted liquid–liquid extraction in acetonitrile/water mixtures. J Chromatogr A 1308:58–62
Amer S, Kadi AA, Darwish HW, Attwa MW (2017) Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation. RSC Adv 7(8):4479–4491
Amer SM, Kadi AA, Darwish HW, Attwa MW (2017) LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. Chem Cent J 11(1):136